Trial Profile
A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Etoricoxib (Primary) ; Indometacin
- Indications Gout; Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 23 Jan 2010 New trial record